Connect your AI

Nektar Therapeutics NKTR AFS Securities

AFS Securities at other companies

Kymera TherapeuticsKYMR

$894.72M+186%

Arcus BiosciencesRCUS

$54M+575%

Nuvation BioNUVB

$365.13M-21.8%

IncyteINCY

——

Other financials

Income statement

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Nektar Therapeutics's AFS securities?: Nektar Therapeutics (NKTR) reported AFS securities of $162.99M in Q1 2026.
How has Nektar Therapeutics's AFS securities changed year-over-year?: Nektar Therapeutics's AFS securities increased by 7973.0% year-over-year, from $2.02M to $162.99M.
What is the long-term trend for Nektar Therapeutics's AFS securities?: Over 5 years (2020 to 2025), Nektar Therapeutics's AFS securities has grown at a -100.0% compound annual growth rate (CAGR), from $136.66M to $0.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.